JP6929934B2 - 好酸球性食道炎を処置する方法 - Google Patents

好酸球性食道炎を処置する方法 Download PDF

Info

Publication number
JP6929934B2
JP6929934B2 JP2019508847A JP2019508847A JP6929934B2 JP 6929934 B2 JP6929934 B2 JP 6929934B2 JP 2019508847 A JP2019508847 A JP 2019508847A JP 2019508847 A JP2019508847 A JP 2019508847A JP 6929934 B2 JP6929934 B2 JP 6929934B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
week
hours
orally disintegrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019508847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528272A5 (cg-RX-API-DMAC7.html
JP2019528272A (ja
Inventor
メルツァー，ブライアン
カマー，ゲイル
Original Assignee
アデア ファーマシューティカルズ，インコーポレイテッド
アデア ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アデア ファーマシューティカルズ，インコーポレイテッド, アデア ファーマシューティカルズ，インコーポレイテッド filed Critical アデア ファーマシューティカルズ，インコーポレイテッド
Publication of JP2019528272A publication Critical patent/JP2019528272A/ja
Publication of JP2019528272A5 publication Critical patent/JP2019528272A5/ja
Priority to JP2021131290A priority Critical patent/JP7526143B2/ja
Application granted granted Critical
Publication of JP6929934B2 publication Critical patent/JP6929934B2/ja
Priority to JP2024115475A priority patent/JP2024164004A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electronic Switches (AREA)
JP2019508847A 2016-08-18 2017-08-18 好酸球性食道炎を処置する方法 Expired - Fee Related JP6929934B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021131290A JP7526143B2 (ja) 2016-08-18 2021-08-11 好酸球性食道炎を処置する方法
JP2024115475A JP2024164004A (ja) 2016-08-18 2024-07-19 好酸球性食道炎を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376703P 2016-08-18 2016-08-18
US62/376,703 2016-08-18
US201762461317P 2017-02-21 2017-02-21
US62/461,317 2017-02-21
US201762489292P 2017-04-24 2017-04-24
US62/489,292 2017-04-24
PCT/US2017/047474 WO2018035393A1 (en) 2016-08-18 2017-08-18 Methods of treating eosinophilic esophagitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131290A Division JP7526143B2 (ja) 2016-08-18 2021-08-11 好酸球性食道炎を処置する方法

Publications (3)

Publication Number Publication Date
JP2019528272A JP2019528272A (ja) 2019-10-10
JP2019528272A5 JP2019528272A5 (cg-RX-API-DMAC7.html) 2020-09-03
JP6929934B2 true JP6929934B2 (ja) 2021-09-01

Family

ID=61197039

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019508847A Expired - Fee Related JP6929934B2 (ja) 2016-08-18 2017-08-18 好酸球性食道炎を処置する方法
JP2021131290A Active JP7526143B2 (ja) 2016-08-18 2021-08-11 好酸球性食道炎を処置する方法
JP2024115475A Pending JP2024164004A (ja) 2016-08-18 2024-07-19 好酸球性食道炎を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021131290A Active JP7526143B2 (ja) 2016-08-18 2021-08-11 好酸球性食道炎を処置する方法
JP2024115475A Pending JP2024164004A (ja) 2016-08-18 2024-07-19 好酸球性食道炎を処置する方法

Country Status (11)

Country Link
US (7) US10105315B2 (cg-RX-API-DMAC7.html)
EP (1) EP3500264A4 (cg-RX-API-DMAC7.html)
JP (3) JP6929934B2 (cg-RX-API-DMAC7.html)
KR (3) KR20210095973A (cg-RX-API-DMAC7.html)
AU (2) AU2017312660B2 (cg-RX-API-DMAC7.html)
CA (1) CA3034264A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ750754A (cg-RX-API-DMAC7.html)
RU (1) RU2766577C2 (cg-RX-API-DMAC7.html)
TW (2) TWI728172B (cg-RX-API-DMAC7.html)
UY (1) UY37370A (cg-RX-API-DMAC7.html)
WO (1) WO2018035393A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2013506683A (ja) 2009-10-01 2013-02-28 アプタリス ファーマテク，インコーポレイテッド 経口投与型コルチコステロイド組成物
BR112015005048A8 (pt) 2012-09-07 2018-01-30 Regeneron Pharma métodos para tratar dermatite atópica por administração de antagonista il-4r
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP6526037B2 (ja) 2014-02-28 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CA3035202A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
JP2021523188A (ja) 2018-05-13 2021-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11672959B2 (en) * 2019-01-18 2023-06-13 Intersect Ent, Inc. Expandable member systems and methods for drug delivery
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
JP2022530554A (ja) 2019-05-02 2022-06-29 インターセクト エント インターナショナル ゲーエムベーハー バルーン拡張デバイス
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
US11328089B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Built-in legal framework file management
US11106813B2 (en) * 2019-09-20 2021-08-31 International Business Machines Corporation Credentials for consent based file access
US11188680B2 (en) 2019-09-20 2021-11-30 International Business Machines Corporation Creating research study corpus
US11443056B2 (en) 2019-09-20 2022-09-13 International Business Machines Corporation File access restrictions enforcement
US11321488B2 (en) 2019-09-20 2022-05-03 International Business Machines Corporation Policy driven data movement
US11327665B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Managing data on volumes
KR20220074915A (ko) * 2019-10-01 2022-06-03 엘로디 파마슈티컬스, 엘.피. 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
US11075010B1 (en) * 2020-03-19 2021-07-27 Insight RX, Inc. Pharmacology model optimization based on distributed data acquisition
US20210330900A1 (en) * 2020-04-22 2021-10-28 Topical Sinus Therapeutics, Inc. TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE)
BR112022022235A2 (pt) * 2020-05-22 2023-03-28 Regeneron Pharma Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r
MX2023012301A (es) * 2021-04-20 2024-01-08 Ellodi Pharmaceuticals L P Metodos para tratar estenosis esofagicas.
CN117715641A (zh) * 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
CN119997959A (zh) * 2022-07-28 2025-05-13 威斯康星州医药大学股份有限公司 用于治疗反流的缓释口服福沙那韦制剂
WO2025128792A1 (en) * 2023-12-13 2025-06-19 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and depleting mast cell

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SE378109B (cg-RX-API-DMAC7.html) 1972-05-19 1975-08-18 Bofors Ab
DE2260384C3 (de) 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US4080448A (en) 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
ZA892859B (en) 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
DK0735884T3 (da) 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
DE19606151C2 (de) 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20010014340A1 (en) 1996-06-14 2001-08-16 Motohiro Ohta Intrabuccally rapidly disintegrating tablet
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
RO118174B1 (ro) 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
BR122012030847B1 (pt) 1999-04-23 2021-07-06 Leo Pharma A/S Composição farmacêutica não aquosa para uso dermatológico, e, uso da mesma
GB2354007B (en) 1999-09-11 2003-10-22 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20030050312A1 (en) 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
EP2014307A3 (en) 2001-03-13 2010-12-08 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
KR100642976B1 (ko) 2001-05-10 2006-11-10 아스텔라스세이야쿠 가부시키가이샤 구강내 신속 붕괴성 정제 및 이의 제조방법
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP4173670B2 (ja) 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
NZ536294A (en) 2002-05-03 2005-05-27 Janssen Pharmaceutica Nv Polymeric microemulsions of amphiphilic diblock copolymers
US20040106663A1 (en) 2002-09-06 2004-06-03 Talley John Jeffrey Inhibitors of fungal invasion
AU2003272450A1 (en) 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004024960D1 (de) 2003-01-21 2010-02-25 Nippon Shinyaku Co Ltd Rasch in der mundhöhle schmelzende tablette
NZ541167A (en) 2003-01-31 2008-07-31 Orexo Ab A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050009848A1 (en) 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US20060134054A1 (en) 2003-12-19 2006-06-22 Council Of Scientific And Industrial Research Polymer composition for pH dependent dissolution behavior and process for preparation thereof
DK1748756T3 (da) 2004-03-10 2009-06-15 Bayer Schering Pharma Ag Præparater som omfatter drospirenon der er molekylært dispergeret
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
ES2282831T3 (es) 2004-09-09 2007-10-16 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Comprimidos que contienen domperidona rapidamente dispersables en agua.
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007158225A (ja) 2005-12-08 2007-06-21 Canon Inc 露光装置
CN1985799B (zh) 2005-12-19 2011-11-09 量子高科（北京）研究院有限公司 口腔崩解制剂的制备方法
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1958613A1 (en) 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
US20090074862A1 (en) 2007-04-13 2009-03-19 Luigi Schioppi Low-dose doxepin formulations and methods of making and using the same
US20150231156A1 (en) * 2007-11-13 2015-08-20 Meritage Pharma, Inc. Corticosteroid compositions
HRP20180408T1 (hr) 2007-11-13 2018-04-20 Meritage Pharma, Inc. Pripravci za liječenje gastrointestinalnih upala
US20090123551A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
MX2010006326A (es) 2007-12-10 2010-10-04 Eurand Inc Comprimidos de desintegracion oral que comprenden difenhidramina.
WO2009086046A1 (en) 2007-12-21 2009-07-09 Eurand, Inc. Orally disintegrating tablet compositions of temazepam
JP2009173552A (ja) 2008-01-21 2009-08-06 Lion Corp 胃腸薬
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
ATE498396T1 (de) 2008-07-21 2011-03-15 Falk Pharma Gmbh Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes
MX2011001487A (es) 2008-08-08 2011-03-30 Mcneil Ppc Inc Uso de sucralosa como agente granulante.
PL2328553T3 (pl) 2008-08-20 2020-12-14 The Regents Of The University Of California Kortykosteroidy do leczenia chorób zapalnych przewodu pokarmowego
MX2011007578A (es) 2009-01-15 2011-08-04 Nestec Sa Metodos para diagnosticar y tratar la disfagia.
JP2012518655A (ja) 2009-02-23 2012-08-16 アプタリス ファーマテック インコーポレイテッド プロトンポンプ阻害剤を含む制御放出組成物
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
JP2013506683A (ja) 2009-10-01 2013-02-28 アプタリス ファーマテク，インコーポレイテッド 経口投与型コルチコステロイド組成物
WO2011066287A1 (en) 2009-11-30 2011-06-03 Eurand, Inc. Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
EP2585075B8 (en) * 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
EP2646003B1 (en) 2010-12-02 2020-06-03 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
EP2665408B1 (en) 2011-01-18 2021-08-11 University Health Network (UHN) Device for swallowing impairment detection
EP2667777B1 (en) 2011-01-28 2016-08-10 Nestec S.A. Apparatuses for diagnosing swallowing dysfunction
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
WO2014016754A2 (en) 2012-07-26 2014-01-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
FI2886108T4 (fi) * 2013-12-23 2023-02-22 Optimoitu farmaseuttinen koostumus ruokatorven tulehduksellisten muutosten hoitoon
WO2015142739A1 (en) 2014-03-17 2015-09-24 Children's Hospital Medical Center Genetic test for determining susceptibility for eosinophilic esophagitis
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
US9980975B2 (en) * 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US10869592B2 (en) 2015-02-23 2020-12-22 Uroviu Corp. Handheld surgical endoscope
HUE067896T2 (hu) 2016-04-27 2024-11-28 Abbvie Mfg Management Unlimited Company Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CA3090832A1 (en) 2018-02-21 2019-08-29 Adare Pharmaceuticals Us, L.P. Methods of managing eosinophilic esophagitis
KR20220074915A (ko) 2019-10-01 2022-06-03 엘로디 파마슈티컬스, 엘.피. 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
WO2022020464A1 (en) 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
MX2023012301A (es) 2021-04-20 2024-01-08 Ellodi Pharmaceuticals L P Metodos para tratar estenosis esofagicas.

Also Published As

Publication number Publication date
RU2766577C2 (ru) 2022-03-15
KR20210095973A (ko) 2021-08-03
KR20230167146A (ko) 2023-12-07
RU2019105805A3 (cg-RX-API-DMAC7.html) 2020-11-13
UY37370A (es) 2018-01-02
TWI777515B (zh) 2022-09-11
WO2018035393A1 (en) 2018-02-22
US20190008760A1 (en) 2019-01-10
US20230414498A1 (en) 2023-12-28
US20210346278A1 (en) 2021-11-11
US11684571B2 (en) 2023-06-27
US20250170057A1 (en) 2025-05-29
US11896710B2 (en) 2024-02-13
AU2017312660B2 (en) 2023-06-29
US11026887B2 (en) 2021-06-08
US20210275438A1 (en) 2021-09-09
JP2019528272A (ja) 2019-10-10
JP2024164004A (ja) 2024-11-26
EP3500264A4 (en) 2020-04-29
TW202206079A (zh) 2022-02-16
AU2023233115A1 (en) 2023-10-12
CA3034264A1 (en) 2018-02-22
US20180133145A1 (en) 2018-05-17
US10105315B2 (en) 2018-10-23
TWI728172B (zh) 2021-05-21
JP7526143B2 (ja) 2024-07-31
NZ750754A (en) 2023-02-24
US20200368147A1 (en) 2020-11-26
KR20190039769A (ko) 2019-04-15
RU2019105805A (ru) 2020-09-18
US12059494B2 (en) 2024-08-13
EP3500264A1 (en) 2019-06-26
TW201808304A (zh) 2018-03-16
JP2021178866A (ja) 2021-11-18
AU2017312660A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
JP6929934B2 (ja) 好酸球性食道炎を処置する方法
US12310976B2 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
TW202116304A (zh) 非鎮靜之右美托咪啶(dexmedetomidine)治療方案
JP2023168451A (ja) 好酸球性食道炎を管理する方法
JP2005519901A (ja) 新規の置換ベンゾイミダゾール剤形とそれを使用する方法
US12364683B2 (en) Non-sedating dexmedetomidine treatment regimens
KR20220074915A (ko) 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
US20230270744A1 (en) Methods of Administering Elagolix
US20220257597A1 (en) Methods of Administering Elagolix
NZ790981A (en) Methods of treating eosinophilic esophagitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200721

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200721

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210811

R150 Certificate of patent or registration of utility model

Ref document number: 6929934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees